BridgeBio secondary offering: KKR sells 5M shares at $78, no proceeds to company

BridgeBio Pharma, Inc.

KKR Genetic Disorder L.P. selling 5,000,000 shares at $78.00/share; expected close Aug 17, 2026.
Company receives no proceeds; offering oversubscribed per Aug 14 press release.
Joint book-runners: William Blair, Goldman Sachs & Co. LLC, KKR Capital Markets LLC.
Offering launched Aug 13, priced Aug 14; aims to diversify shareholder base toward long-term ownership.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.